Navigation Links
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Date:3/16/2009

PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, March 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court of the Southern District of New York against Barr Laboratories, Inc. ("Barr") for infringement of three of Shire's patents: U.S. Patent No. 5,968,976 ("'976 Patent"); U.S. Patent No. 7,381,428 ("'428"); and U.S. Patent No. 7,465,465 ("'465").

The lawsuit was filed in response to an ANDA (Abbreviated New Drug Applications) filed by Barr seeking FDA approval to market and sell generic versions of Shire's 500 mg, 750 mg, and 1 g FOSRENOL(R) (Lanthanum Carbonate) products.

Under the Hatch-Waxman Act, because Shire filed its patent infringement lawsuit within 45 days of receiving Barr's Paragraph IV notification letter, the FDA must refrain from approving Barr's ANDA for 30 months, or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier. The stay on generic approval will expire on April 26, 2012 unless terminated earlier.

Shire is confident in its intellectual property portfolio protecting FOSRENOL(R), and will enforce its patents against infringers to the fullest extent allowed by law.

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global right
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/18/2014)... Sarasota, FL (PRWEB) November 17, 2014 ... novel point-of-care diagnostic tests – today announces its ... Control and Prevention’s (CDC) Get Smart About Antibiotics ... Antibiotics Week is a national campaign designed to ... local health departments, and non-profit and for-profit partners ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... CAMBRIDGE, England, June 25 ... service discovery services company at the,forefront of drug discovery ... Ahmedabad, India offering physio-chemical and CYP450 assays. , ... Biology Affiliate Partnership with,Hypoxium Ltd. UK. Hypoxium has specialist ...
... announced the winners of the NWO/Spinoza Prize for 2009. Two ... authors, Marten Scheffer and Albert van den Berg. The prize, ... Dutch award in science and is given for outstanding, pioneering ... EUR 1.5 million, but this year, each of the three ...
... June 24 KBI Biopharma, Inc. (KBI) announced today ... line generation with Crucell,s PER.C6(R) human cell line platform, ... on May 6, 2009. Under that agreement, KBI joins ... generation partner for licensees of the PER.C6(R) cell lines. ...
Cached Biology Technology:O2h and Hypoxium Announce an Agreement to Offer Hypoxium's Specialised In Vitro, Cell-Based Oncology Assays via O2h's Biology Affiliate Program 2KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R) 2
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... December 10, 2013, Shenzhen, China - Chinese researchers ... Medicine, BGI and other institutes identified the recurrent ... Yang 1) are related with insulinoma oncogenesis, implicating ... of functional pancreatic neuroendocrine tumors (PNETs). The latest ...
... has one of the fastest growing human populations in the ... density isn,t yet that high, the number of conflicts between ... on land areas grows. Angela Mwakatobe, who recently defended ... (NTNU) in Trondheim, has studied villages at various distances from ...
... a study led by McGill researcher Sarah Kimmins suggests that ... role in the health of their offspring. It also raises ... of food insecurity. The research focused on vitamin B9, ... green leafy vegetables, cereals, fruit and meats. It is well ...
Cached Biology News:Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma 2Serengeti's animals under pressure 2Serengeti's animals under pressure 3You are what your father eats 2
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Biology Products: